AU3808478A - Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid - Google Patents

Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid

Info

Publication number
AU3808478A
AU3808478A AU38084/78A AU3808478A AU3808478A AU 3808478 A AU3808478 A AU 3808478A AU 38084/78 A AU38084/78 A AU 38084/78A AU 3808478 A AU3808478 A AU 3808478A AU 3808478 A AU3808478 A AU 3808478A
Authority
AU
Australia
Prior art keywords
withall
treatment
eicosapentaenoic acid
thromboembolic conditions
thromboembolic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU38084/78A
Other versions
AU527784B2 (en
Inventor
Et Al Hans Olaf Bang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyerberg Jorn Dr
Original Assignee
Dyerberg Jorn Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2357578A external-priority patent/GB1604554A/en
Application filed by Dyerberg Jorn Dr filed Critical Dyerberg Jorn Dr
Publication of AU3808478A publication Critical patent/AU3808478A/en
Application granted granted Critical
Publication of AU527784B2 publication Critical patent/AU527784B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C15/00—Butter; Butter preparations; Making thereof
    • A23C15/12—Butter preparations
    • A23C15/126—Butter containing a minority of vegetable oils; Enrichment of butter with fatty acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU38084/78A 1978-05-26 1978-07-17 Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid Expired AU527784B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB7823575 1978-05-26
GBGB7823574 1978-05-26
GB2357478 1978-05-26
GB2357578A GB1604554A (en) 1978-05-26 1978-05-26 Pharmaceutical and food formulations

Publications (2)

Publication Number Publication Date
AU3808478A true AU3808478A (en) 1980-01-17
AU527784B2 AU527784B2 (en) 1983-03-24

Family

ID=26256599

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38084/78A Expired AU527784B2 (en) 1978-05-26 1978-07-17 Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid

Country Status (13)

Country Link
JP (1) JPS5515444A (en)
AU (1) AU527784B2 (en)
CA (1) CA1151068A (en)
CH (1) CH644267A5 (en)
DE (1) DE2831507A1 (en)
ES (1) ES8104983A1 (en)
FR (1) FR2426461A1 (en)
IE (1) IE48287B1 (en)
IL (1) IL55227A (en)
IT (1) IT1116505B (en)
NL (1) NL191332C (en)
NZ (1) NZ187908A (en)
SE (1) SE448678B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS59172416A (en) * 1983-03-18 1984-09-29 Terumo Corp Fat transfusion solution
FR2548021B1 (en) * 1983-06-29 1986-02-28 Dick P R PROLONGED AND CONTINUOUS DERMAL PHARMACEUTICAL COMPOSITIONS BASED ON ESSENTIAL FATTY ACIDS
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
JPS60132916A (en) * 1983-12-21 1985-07-16 Nisshin Oil Mills Ltd:The Food or drug for preventing thrombosis
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
JPH0748991B2 (en) * 1984-08-29 1995-05-31 日本油脂株式会社 Tube feeding composition
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
NL9401743A (en) * 1994-10-20 1996-06-03 Prospa Bv Salts of amino alcohols and pharmaceutical formulations containing them.
DE19503993A1 (en) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Enteral product contg n-3-fatty acid or deriv and medium chain length tri:glyceride
DE10056351A1 (en) * 2000-11-14 2002-05-29 Weylandt Karsten Henrich Pharmaceutical preparation containing omega-3 fatty acids and other active substances e.g. an antiinflammatory, cyclooxygenase II inhibitor, 5-lipoxygenase inhibitor or platelet aggregation inhibitor
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
NZ789295A (en) 2009-04-29 2024-02-23 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ627238A (en) 2009-04-29 2016-02-26 Amarin Pharmaceuticals Ie Ltd Stable pharmaceutical composition comprising ethyl eicosapentaenoate
CN114053258A (en) 2009-06-15 2022-02-18 阿马里纳药物爱尔兰有限公司 Compositions and methods for lowering triglycerides without increasing LDL-C levels in subjects on concomitant statin therapy
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
JP2015522029A (en) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド Methods to reduce the risk of cardiovascular events in patients on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
KR20150115745A (en) 2013-02-06 2015-10-14 에이전시 포 사이언스, 테크놀로지 앤드 리서치 Methods for reducing aggregate content in protein preparations
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (en) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 Method of reducing the risk of a cardiovascular event in a subject

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE319677B (en) * 1965-03-27 1970-01-19 Sumitomo Chemical Co
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
GB1476624A (en) * 1973-05-30 1977-06-16 Cepbepe Tranquiliser medicaments
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
JPS6257605A (en) * 1985-09-05 1987-03-13 Kaizuka Kazutoshi Method for extracting effective component from multiple-element mineral

Also Published As

Publication number Publication date
ES480921A0 (en) 1981-05-16
CA1151068A (en) 1983-08-02
JPS5515444A (en) 1980-02-02
IL55227A (en) 1982-12-31
NL191332C (en) 1995-06-01
NL191332B (en) 1995-01-02
IE48287B1 (en) 1984-11-28
IT1116505B (en) 1986-02-10
FR2426461B1 (en) 1983-02-11
DE2831507A1 (en) 1979-11-29
CH644267A5 (en) 1984-07-31
IL55227A0 (en) 1978-09-29
DE2831507C2 (en) 1989-07-13
IE791023L (en) 1979-11-26
IT7947717A0 (en) 1979-01-19
NZ187908A (en) 1984-05-31
SE7904570L (en) 1979-11-27
FR2426461A1 (en) 1979-12-21
ES8104983A1 (en) 1981-05-16
NL7904144A (en) 1979-11-28
AU527784B2 (en) 1983-03-24
SE448678B (en) 1987-03-16

Similar Documents

Publication Publication Date Title
AU527784B2 (en) Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
AU4469379A (en) Phenoxyalkylcarboxylic acid derivatives
AU4413779A (en) Modified azulmic acid
AU515455B2 (en) Acid tinplating solution
AU531501B2 (en) 3-quinoline-carboxylic acid
AU4748079A (en) Anti-corrosion treatment
JPS54163561A (en) Manufacture of 22*6*methoxyy2**naphthyl* propionic acid
AU521011B2 (en) 1,3-dibenzoic acid esters of 17alpha-ethynyl-7alpha-methyl- delta1,3,5,(10) -oestratriene-1,3,17beta-triol and their manufacture and use
AU523428B2 (en) Process of strengthening dilute phosphoric acid
ZA792773B (en) Derivatives of 4,5-dihydro-4-oxofuran-2-carboxylic acid
AU527930B2 (en) 1,3,4-thiadiazole-2-carboxylic acid derivatives
DE2961465D1 (en) Process for the preparation of 3,3-dimethyl-2-oxo-butanoic acid
AU4377179A (en) 1-naphthyl-acetic acid derivatives
IL60108A0 (en) Process for the manufacture of 5-mercapto-1,2,3-triazoles and novel 1,2,3-thiadiazole-5-carbohydroxamic acid derivatives
DE2961335D1 (en) Process for the preparation of percarboxylic acid solutions
GB2058775B (en) Preparation of 2,5-diketogluconic acid
JPS54157540A (en) Manufacture of 22*33benzoylphenyl*propionic acid
AU5131279A (en) Isocyanocarboxylic acid amides
GB2034737B (en) Process for the preparation of 1,4-diaminoanthraquinone-2,3-disulphonic acid
AU516205B2 (en) Manufacture of furancarbvoxylic acid anilides
SU632685A1 (en) Method of isolating 2,3-oxynaphthoic acid
AU536075B2 (en) 4,4 dimethyl-4-sila fatty acid amides
AU498866B1 (en) Reduction of 2, 5-diketogluconic acid
AU519340B2 (en) Preparation of 2,5-diketogluconic acid
AU5210679A (en) O-ethyl-s-n-propyl-dithiophosphoryloxy-acetic acid n-methyl- anilide